Minneapolis, MN, Sept. 26, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a novel cardiac electrophysiology (EP) signal acquisition and analysis system, today announced they have provided an unrestricted educational grant to The 11th International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy hosted by The Mount Sinai Hospital in New York and the University of Pennsylvania Health System in Philadelphia to be held at the New York Hilton Midtown on October 7 and 8, 2016. The course has been developed to meet the educational needs of electrophysiologists and other physicians with an interest in the pathophysiology and management of ventricular arrhythmias.
The purpose of the Annual International Symposium on Ventricular Arrhythmias is to provide a current review of new information on the basic pathophysiology of ventricular arrhythmias and to provide an in-depth understanding of the current management strategies used for the management of ventricular arrhythmias in various disease states.
Greg Cash, President and Chief Executive of BioSig Technologies, said, “Providing support for this important symposium underscores BioSig’s commitment to helping to improve outcomes in patients with complex arrhythmias, in this case ventricular tachycardias and ventricular fibrillation, which result in over 450,000 sudden cardiac deaths per year in the United States alone.”
Jay Millerhagen, BioSig’s VP of Clinical Research plans to attend the symposium and will be available to meet those interested in reviewing the Company’s pre-clinical work to date. To set up a meeting, please email jmillerhagen@biosigtech.com .
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $4 billion EP marketplace (1) ( biosigtech.com ). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
The PURE EP(TM) System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system engineered to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1), making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig has partnered with Minnetronix on technology development and is working toward a FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center; and, has performed pre-clinical studies at Mayo Clinic in Minnesota. Additionally, an Advanced Research Program at Mayo Clinic began in June 2016. The Company is also collaborating with other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, Ohio and Mount Sinai Medical Center in New York.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; AF includes left atrial tachycardia, left WPW, left atrial flutter.
Investor Relations: Brian McLaughlin BioSig Technologies, Inc. bmclaughlin@biosigtech.com 917-370-9817 Robert Haag IRTH Communications BSGM@irthcommunications.com 866-976-4784
